Summary:
- Teva Pharmaceutical Industries presented post-hoc data for TEV-749, a once-monthly subcutaneous injectable formulation of olanzapine, demonstrating high rates of stabilization in adult patients with schizophrenia.
- The clinical findings emphasize the long-term efficacy and pharmacokinetic stability of the drug, suggesting a potential advancement in maintenance therapy for managing chronic psychiatric conditions.